RADIOPHARM THERANOSTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.045 AUD | -2.17% |
|
0.00% | -39.19% |
| Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
| Feb. 29 | Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 26.42 | 23.73 | 13.34 | - | - |
| Enterprise Value (EV) 1 | 26.42 | 23.73 | 18.61 | 17.29 | 16.63 |
| P/E ratio | -0.9 x | -0.95 x | -0.42 x | -0.42 x | -0.45 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 125 x | - | - | - |
| EV / Revenue | - | 125 x | - | - | - |
| EV / EBITDA | -2.14 x | -1.17 x | -0.66 x | -0.53 x | -0.46 x |
| EV / FCF | - | -1,481,782 x | - | - | - |
| FCF Yield | - | -0% | - | - | - |
| Price to Book | - | 0.83 x | - | - | - |
| Nbr of stocks (in thousands) | 255,433 | 339,313 | 451,796 | - | - |
| Reference price 2 | 0.1034 | 0.0699 | 0.0295 | 0.0295 | 0.0295 |
| Announcement Date | 8/30/22 | 8/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.1893 | - | - | - |
| EBITDA 1 | - | -12.36 | -20.19 | -28.29 | -32.65 | -36.46 |
| EBIT 1 | - | -14.42 | -22.33 | -29.03 | -31.78 | -37.01 |
| Operating Margin | - | - | -11,796.17% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -20.85 | -22.38 | -29.01 | -31.76 | -37 |
| Net income 1 | -0.3503 | -20.88 | -22.41 | -29.01 | -31.76 | -37 |
| Net margin | - | - | -11,838.62% | - | - | - |
| EPS 2 | - | -0.1152 | -0.0733 | -0.0695 | -0.0695 | -0.0660 |
| Free Cash Flow | - | - | -16.01 | - | - | - |
| FCF margin | - | - | -8,459.64% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/23/21 | 8/30/22 | 8/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.1013 | 0.0945 | 0.1974 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | -14.55 | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | -8.476 | -14.28 | - | - | - | - | - | - |
| Net margin | - | - | -4,293.45% | - | - | - | - | - | - | - |
| EPS | - | - | -0.0307 | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/28/22 | 2/28/23 | 2/28/23 | 8/31/23 | 2/29/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 5.28 | 3.96 | 3.3 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.1865 x | -0.1212 x | -0.0905 x |
| Free Cash Flow | - | - | -16 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | -120% | -127% | -132% |
| ROA (Net income/ Total Assets) | - | - | - | -64.5% | -70.7% | -75.2% |
| Assets 1 | - | - | - | 44.98 | 44.93 | 49.21 |
| Book Value Per Share | - | - | 0.0800 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 0.99 | 0.03 | 0.03 | 0.03 |
| Capex / Sales | - | - | 523.56% | - | - | - |
| Announcement Date | 11/23/21 | 8/30/22 | 8/31/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0295
USD
Average target price
0.317
USD
Spread / Average Target
+973.93%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.19% | 13.55M | |
| +25.73% | 661B | |
| +26.74% | 566B | |
| -6.71% | 352B | |
| +18.85% | 332B | |
| +3.33% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.36% | 145B |
- Stock Market
- Equities
- RAD Stock
- Financials Radiopharm Theranostics Limited
